Symptoms of neuropathic pain vary greatly. Symptoms may range from burning and lancinating to deep and aching. They may be described as hyperalgesia, allodynia, or hyperpathia. Patients may be hesitant to move the painful area of the body, and the pain may persist even after the underlying cause has been resolved. Listed below are some of the common symptoms of neuropathic pain.
Nerves near an amputation send faulty signals to the brain, which in turn causes phantom pain. Treatments for neuropathic pain aim to identify the underlying disease, provide pain relief, and improve quality of life. Some treatment options include nonsteroidal anti-inflammatory drugs. If no treatment can be found, patients may experience a relapse of symptoms. While nonsteroidal anti-inflammatory drugs may be prescribed, these drugs will only be temporary.
Although neuropathic pain has no definitive cause, increased visits to health care providers and drug prescriptions suggest the presence of a neurological disease. Clinical examination of sensory signs, including pain intensity, distribution, and frequency, can also suggest a neurologic disease. However, a definitive diagnosis requires an objective test. Ultimately, a multidisciplinary approach to neuropathic pain is needed to find a cure for the condition. But until then, the following suggestions will help guide treatment.
The Nigeria neuropathic pain management drugs market is estimated to be valued at US$ 8.1 million in 2021 and is expected to exhibit a CAGR of 3.2% over the forecast period (2021-2028).
𝐓𝐨 𝐠𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.coherentmarketinsights.com/insight/request-sample/4918
The local production of neuropathic pain management drugs is expected to bring profitable growth opportunities in the market. This is expected to drive growth of the Nigeria neuropathic pain management drugs market over the forecast period.
There are limited number of players in Nigeria such as May & Baker Nigeria Plc. and CHI Pharmaceuticals Limited who manufacture analgesics, NSAIDs, and other pain medications. Majority of these medications are imported from countries in North America, Europe, and the Asia Pacific regions. Manufacturers in the Asia Pacific region export generic medications to the country in large amounts.
Manufacturers have significant scope to produce generic products in the country with cGMP guidelines and build a scalable business. Majority of drugs such as TCAs, and anticonvulsants are imported in the country, therefore manufacturing these drugs into the country could prove to be a sustainable business.
Presence of branded as well as generic versions of drugs for the treatment of neuropathic pain is expected to drive the market growth over the forecast period.
Key players in the market such as GlaxoSmithKline, Pfizer, and others offer products in Nigeria for management of neuropathic pain. Moreover, several manufacturers from India and China export generic drugs for management of neuropathic pain to the country which are cheaper versions of off-patent drugs. Generic versions of tricyclic antidepressants, anticonvulsants, and NSAIDs are available for under US$ 1 per tablet which makes them affordable for patients. Moreover, local manufacturers such as Biofem Group, May & Baker Nigeria Plc, CHI Pharmaceuticals Limited, and others offer analgesics as well as other drugs in the Nigerian market.
𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4918
Nigeria Neuropathic Pain Management Drugs Market– Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic and lockdown in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. COVID-19 frequently causes central or peripheral neurological complications, it is predicted that a number of the chronic pain complications associated with COVID-19 will be neuropathic. Even though COVID-19 most commonly exhibits acute respiratory symptoms but other symptoms mostly involves joint pain, muscle pain, and headache at the acute phase, or pain due to critical illness myopathy or polyneuropathy. Neuropathic pain may be cause indirectly caused by SARS-CoV-2 or by COVID-19 after ICU treatment. The pervasiveness of persistent pain after ICU has been expected to range from 28% to 77%. Another possible mechanism responsible for neuropathic pain after COVID-19 is the indirect or direct impact of the virus on the nervous system.
Nigeria Neuropathic Pain Management Drugs Market: Restraint
The Nigeria pharmaceutical market suffers from several challenges such as scarce local production of pain management drugs, problem of counterfeit drugs, opioid drugs abuse (tramadol), heavy reliance on import of drugs from international manufacturers, and others. These factors are inadvertently affecting all the sectors of the pharmaceutical industry in Nigeria including the neuropathic pain management drugs market.
For instance, in November 2018, National Drug Law Enforcement Agency (NDLEA), Nigeria, seized 581 million Tramadol tablets which were illicitly brought into the country.
Moreover, other factors such as low awareness about neuropathic conditions and the management of these conditions, as well as lack of proper diagnostic techniques is expected to restrain growth of the neuropathic pain management drugs market in Nigeria over the forecast period.
Key Players
Key players operating in the Nigeria neuropathic pain management drugs market include Pfizer Inc., Novartis AG, GlaxoSmithKline Plc, and Biofemgroup Ltd.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.coherentmarketinsights.com/insight/buy-now/4918
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- Regulatory Scenario
- Reimbursement Scenario
- Mergers & Acquisitions
- Market Dynamics
- Nigeria Neuropathic Pain Management Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- Nigeria Neuropathic Pain Management Drugs Market, By Drug Class, 2021 – 2028, (US$ Mn.)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Serotonin–norepinephrine Reuptake Inhibitors (SNRIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Introduction
- Nigeria Neuropathic Pain Management Drugs Market, By Disease Indication, 2021 – 2028, (US$ Mn.)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Diabetic Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Chemotherapy-induced Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Introduction
- Nigeria Neuropathic Pain Management Drugs Market, By Distribution Channel, 2021 – 2028, (US$ Mn.)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn.)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/nigeria-neuropathic-pain-management-drugs-market-4191
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837